Certara's (CERT) "Overweight" Rating Reaffirmed at Stephens

Stephens reissued their overweight rating on shares of Certara (NASDAQ:CERT - Free Report) in a research note released on Thursday morning,Benzinga reports. They currently have a $17.00 target price on the stock.

Several other equities research analysts have also weighed in on the company. Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. TD Cowen began coverage on Certara in a research note on Thursday. They set a "buy" rating and a $16.00 price objective for the company. Finally, Robert W. Baird cut their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Certara presently has a consensus rating of "Moderate Buy" and an average target price of $15.83.

Certara Price Performance

Shares of Certara stock traded down $0.04 during trading on Thursday, hitting $11.94. 1,908,118 shares of the company's stock traded hands, compared to its average volume of 965,527. The company has a market cap of $1.92 billion, a PE ratio of -59.70, a PEG ratio of 9.29 and a beta of 1.57. The firm's fifty day moving average price is $12.45 and its 200 day moving average price is $11.63. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Remove Ads

Institutional Trading of Certara

Several large investors have recently made changes to their positions in the business. Mackenzie Financial Corp acquired a new position in Certara during the 4th quarter worth about $17,852,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Certara by 16.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,574 shares of the company's stock worth $2,807,000 after purchasing an additional 37,870 shares in the last quarter. Voloridge Investment Management LLC lifted its position in shares of Certara by 269.3% during the fourth quarter. Voloridge Investment Management LLC now owns 275,633 shares of the company's stock worth $2,935,000 after purchasing an additional 201,003 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Certara by 62.7% during the fourth quarter. Squarepoint Ops LLC now owns 94,433 shares of the company's stock valued at $1,006,000 after purchasing an additional 36,386 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Certara by 35.7% in the fourth quarter. Two Sigma Advisers LP now owns 87,500 shares of the company's stock valued at $932,000 after purchasing an additional 23,000 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.